Minodronic acid
Not to be confused with mildronate or medronate.
Names | |
---|---|
IUPAC name
(1-Hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid | |
Other names
Minodronate; YM 529 | |
Identifiers | |
180064-38-4 155648-60-5 (hydrate) | |
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL319144 |
ChemSpider | 115805 |
3164 | |
PubChem | 130956 |
UNII | 40SGR63TGL |
| |
| |
Properties | |
C9H12N2O7P2 | |
Molar mass | 322.15 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis.[1] Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.[2]
References
- ↑ Shridhar Hegde and Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry. 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.
- ↑ Sorbera, L.A.; Castañer, J.; Leeson, P.A. (2002). "Minodronic Acid". Drugs of the Future. 27 (10): 935–941. doi:10.1358/dof.2002.027.10.701186.
This article is issued from Wikipedia - version of the 3/9/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.